{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["27(6)"],"submitter":["Guo F"],"pubmed_abstract":["The treatment of castration-resistant prostate cancer (CRPC) still faces many challenges. Docetaxel is a chemotherapeutic drug commonly used in CRPC patients. However, docetaxel-based chemotherapy usually causes docetaxel resistance, partially due to the resistance of CRPC cells to docetaxel-induced apoptosis. Here, we report that the deubiquitinating enzyme ubiquitin-specific protease 33 (USP33) inhibits docetaxel-induced apoptosis of prostate cancer cells, including androgen-independent prostate cancer cells. USP33 is overexpressed in prostate cancer cells and tissues. We found that knockdown or knockout of USP33 enhanced docetaxel-induced apoptosis of prostate cancer cells, accompanied by increased phosphorylation of the cJUN NH2-terminal kinase (JNK). After blocking docetaxel-induced J"],"journal":["Cell death and differentiation"],"pagination":["1938-1951"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7244590"],"repository":["biostudies-literature"],"pubmed_title":["Deubiquitinating enzyme USP33 restrains docetaxel-induced apoptosis via stabilising the phosphatase DUSP1 in prostate cancer."],"pmcid":["PMC7244590"],"pubmed_authors":["Zhang W","Fang Z","Zhu Y","Guo F","Wang F","Yang B","Zhang C","Sun Y","Shi X"],"additional_accession":[]},"is_claimable":false,"name":"Deubiquitinating enzyme USP33 restrains docetaxel-induced apoptosis via stabilising the phosphatase DUSP1 in prostate cancer.","description":"The treatment of castration-resistant prostate cancer (CRPC) still faces many challenges. Docetaxel is a chemotherapeutic drug commonly used in CRPC patients. However, docetaxel-based chemotherapy usually causes docetaxel resistance, partially due to the resistance of CRPC cells to docetaxel-induced apoptosis. Here, we report that the deubiquitinating enzyme ubiquitin-specific protease 33 (USP33) inhibits docetaxel-induced apoptosis of prostate cancer cells, including androgen-independent prostate cancer cells. USP33 is overexpressed in prostate cancer cells and tissues. We found that knockdown or knockout of USP33 enhanced docetaxel-induced apoptosis of prostate cancer cells, accompanied by increased phosphorylation of the cJUN NH2-terminal kinase (JNK). After blocking docetaxel-induced J","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jun","modification":"2026-04-29T05:26:04.759Z","creation":"2022-02-10T13:09:51.102Z"},"accession":"S-EPMC7244590","cross_references":{"pubmed":["31857702"],"doi":["10.1038/s41418-019-0473-8"]}}